Norway is one of the original six donors to Gavi and has steadily increased its strong long-term political and financial support. Norway’s support to Gavi is advocated at the highest level and is anchored in a strong cross-party political understanding of the value of investing in immunisation. Norway has taken a very active role in Gavi and was the co-host, with the USA, of a meeting in New York in October 2010 which opened for the first Gavi pledging conference. Norway is represented on the Gavi Board in the Board Constituency also comprising Denmark, Netherlands and Sweden.
Norway contributes to the Vaccine Alliance through three funding channels; Direct, IFFIm and AMC. Since 2001, Norway has contributed USD 1.14 billion to Gavi in direct contributions, USD 50 million to AMC and has committed USD 250 million through IFFIm. Norwegian private sector companies, such as DNB and Statoil, as well as private individuals have also provided funding to Gavi.
Note: Proceeds are funds made available to Gavi from donor contributions and commitments, either through cash payments made to Gavi, through frontloading via the capital markets of a future donor commitment to IFFIm, or through AMC funds released to Gavi via the World Bank. IFFIm proceeds are allocated over five year periods coinciding with Gavi’s strategic periods. Proceeds for the current and future strategic periods are indicative until the end of each period and could be revised following changes in market conditions (interest rates or foreign exchange rates), the signing of new pledge(s) and/or changes in IFFIm’s disbursement profile.
Click on Direct, IFFIm, AMC or Matching Fund in the above key to toggle their data on the graph, click again to show the data
Direct Contributions (including Matching Fund)
Received contributions: non-US$ contributions for 2000-2018 and Q1-Q3 2019 are expressed in US$ equivalents using the exchange rates on the dates of receipt. For 2014-2018 and Q1-Q3 2019, where contributions were hedged to mitigate currency risk exposure, these have been expressed using the rates applicable to the hedge agreement.
Future contributions: non-US$ Direct Contribution and Matching Fund pledges for Q4 2019 and years 2020 and beyond are expressed in US$ equivalents using the applicable 'forecast rates' from Bloomberg as at 30 September 2019 or using the rates applicable to any hedge agreement in place.
Received contributions: non-US$ contributions for 2000-2018 and Q1-Q3 2019 are expressed in US$ equivalents as confirmed by the IBRD (World Bank)
Future contributions: non-US$ contributions for Q4 2019 and years 2020 and beyond are expressed in US$ equivalents as follows:
Where the contribution agreement has been signed: contributions are expressed in US$ equivalents using the exchange rates at the time of signing the respective donor grant agreements
Where the contribution agreement has not yet been signed: contributions are expressed in US$ equivalents using the applicable 'forecast rates' from Bloomberg as at 30 September 2019
While IFFIm grants are irrevocable and legally binding, they are subject to a Grant Payment Condition that can potentially reduce the amount due in the event that a programme country is in protracted arrears with the International Monetary Fund. As of 30 September 2019, IFFIm donor grant payments are reduced by 1.5%, however such reductions are not reflected in future contributions figures.
At the pledging conference in London in 2011, the Norwegian Prime Minister committed USD 612 million in direct funding for the period 2011-2015. In addition, the existing agreements of USD 50 million to AMC and NOK 1.5 billion (USD 250 million) to IFFIm. In Berlin 2015, the Prime Minister announced a 50% increase in the Norwegian direct support to Gavi for the period 2016-2020, bringing the total future Norwegian contribution up to NOK 6.25 billion.
Additionally, in 2014 Norway committed NOK 1.14 billion (USD 150 million) for the period 2014-2019 to support the Vaccine Alliance’s effort to complement GPEI’s work, strengthening routine immunisation and introducing inactivated polio vaccine (IPV) in Gavi-supported countries.
Contributions and pledges in total: